MediciNova (NASDAQ:MNOV) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV) in a research report sent to investors on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Trading Down 1.1 %

Shares of MediciNova stock opened at $1.88 on Friday. The firm has a market cap of $92.21 million, a PE ratio of -11.06 and a beta of 0.72. MediciNova has a 12 month low of $1.12 and a 12 month high of $2.38. The stock has a 50 day moving average of $1.44 and a 200 day moving average of $1.41.

MediciNova (NASDAQ:MNOV) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. As a group, equities research analysts forecast that MediciNova will post -0.23 earnings per share for the current fiscal year.

MediciNova Company Profile

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.